Banking Recap

Nuvalent, Inc. to Be Acquired for $10.30B

This transaction is a cash tender offer in which GlaxoSmithKline LLC, an affiliate of GSK plc, is seeking to acquire Nuvalent, Inc. The deal is classified within the healthcare sector, and the disclosed value of the transaction is 10,300,000,000 dollars.

Jul 7, 2026·SEC EDGAR (SC 14D9/A)·pending regulatory·cash tender offer

Deal value

The transaction is sourced from an SEC EDGAR Form SC 14D9/A filing (an amendment to the Schedule 14D-9) published on July 7, 2026. Based on the facts provided, the deal's status is pending regulatory approval.

On the financial advisory side, Centerview served as financial advisor to Nuvalent, the target, and is identified as the lead advisor in this transaction. The source material references an amendment adding bold and underlined language to the "Summary of Centerview Financial Analysis, Selected Public Company Analysis" discussion within the section covering the opinions of the financial advisor to the company board, indicating Centerview rendered a fairness opinion that was subsequently the subject of supplemental disclosure. No financial advisor to GlaxoSmithKline or GSK plc is identified in the facts provided.

On the legal side, Ropes & Gray LLP is identified as legal advisor to Nuvalent, the target, with the source material citing the firm's Boston address at 800 Boylston Street, Prudential Tower, in a copy line for correspondence. No legal advisor to GlaxoSmithKline or GSK plc is identified in the facts provided.

Beyond confirming that the transaction is structured as a cash tender offer with a disclosed value of 10,300,000,000 dollars, no further detail on the specific per-share offer price or the conditions of the tender is included in the facts available.

Several elements of this deal remain undisclosed. No financial or legal advisor to GlaxoSmithKline or GSK plc is named, and no detail on the per-share tender offer price is given beyond the aggregate disclosed value. The fact that this is sourced from an amendment to the Schedule 14D-9 indicates supplemental disclosure was made, but the facts do not specify an expected closing date for the tender offer.